explore -WSS

explore

author：comprehensive 2025-10-01 21:36:16 - browse：2

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： FDA early review: GLP

Wikipedia

WSS

Mitch McConnell episode has important public health takeaway

Adults seen as increasingly susceptible to measles

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Profiling embryos to choose those with higher IQs is almost a reality

Profiling embryos to choose those with higher IQs is almost a reality

Breakthrough Alzheimer’s drugs are inaccessible in rural states

entertainment

explore

entertainment

New air purifier tech could be key to improving indoor air quality

STAT Virtual Event: JPM Recap, Live!

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

New air purifier tech could be key to improving indoor air quality

EQRx, failed developer of low

At least 13 dead in Texas as scorching temps continue

Ascension's ugly legal battle over care for poor patients in Texas

United colonoscopy coverage change 'may cost lives,' doctors say

Micronoma's microbiome cancer diagnostic approach under fire

hotspot

Study suggests new cause of Down syndrome: cells linked to aging

American taxpayers paid $1.8 trillion in health care costs in 2022

What to expect as Trump is arraigned on his Jan 6. indictment

‘Oppenheimer’ and the risks of AI in health care

‘Oppenheimer’ and the risks of AI in health care

What to expect as Trump is arraigned on his Jan 6. indictment

hotspot

Wikipedia

Wikipedia

entertainment